Table 2 Summary of clinical characteristics of the group of untreated patients
Patient number* | P9 | P17 | P25 | P32 | P38 | P41 | P43 | P45 | P46 | P50 | P53 | P61 | P64 | P68 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sex | F | F | F | M | F | F | F | F | F | F | F | F | F | F |
CD27+IgD+ (%) | 8 | 8 | 7 | 6 | 8 | 24 | 6 | 13 | 28 | 3 | 33 | 4 | 3 | 17 |
SLEDAI** score | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLICC*** score | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 5 | 0 | 0 | 1 | 0 |
Disease manifestations****: | ||||||||||||||
Joint | x | x | x | x | x | x | x | x | x | x | x | x | ||
Mucocutaneous | x | x | x | x | x | x | x | x | x | |||||
CNS involvement | x | x | ||||||||||||
Renal involvement | x | x | x | |||||||||||
Hematologic | x | |||||||||||||
Serositis | x | x |